QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:CNCR

Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News

→ Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad)
Free CNCR Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$13.92
▼
$14.46
50-Day Range
$27.45
▼
$32.25
52-Week Range
$25.99
▼
$35.82
Volume
14,963 shs
Average Volume
6,668 shs
Market Capitalization
$12.70 million
Assets Under Management
$17.74 million
Dividend Yield
2.06%
Net Expense Ratio
0.79%
Stock AnalysisDividendHeadlinesHoldingsOwnershipRatingsShort InterestSocial Media

About Range Cancer Therapeutics ETF

The Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.

CNCR ETF News Headlines

March 15, 2024 | msn.com
Large-scale study explores genetic link between colorectal cancer and meat intake
March 11, 2024 | markets.businessinsider.com
Microbix Unveils Test Controls for Head and Neck Cancer
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
March 3, 2024 | nasdaq.com
The Zacks Analyst Blog Highlights CRPT, CNCR, WISE, AIRR and PKB
February 22, 2024 | msn.com
FDA approval of cancer treatment provides new weapon against tumors
February 21, 2024 | msn.com
A watershed moment for cancer therapies has arrived
February 5, 2024 | nz.finance.yahoo.com
ETF S.S.-LONCAR CAN.I.ETF (E18B.BE)
January 24, 2024 | msn.com
Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
January 4, 2024 | markets.businessinsider.com
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
See More Headlines
Receive CNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
Exchange Traded Concepts
Fund Name
Range Cancer Therapeutics ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NASDAQ
Current Symbol
NASDAQ:CNCR
Inception Date
10/13/2015
Fund Manager
Denise M. Krisko
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
Range Cancer Therapeutics Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
79

Fund Statistics

Assets Under Management
$17.74 million
Average Daily Volume
$35,888.60
Discount/Premium
-0.05%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Exchange Traded Concepts, LLC
Custodian
U.S. Bank, N.A.
Distributor
Quasar Distributors, LLC
Transfer Agent
U.S. Bank, N.A.
Trustee
N/A
Lead Market Maker
Jane Street

Options

Optionable
N/A
Short Interest
27,900 shs

Miscellaneous

Outstanding Shares
900,000
Beta
0.90
Creation Unit
50,000
Creation Fee
$150.00
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Ad DTI
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story

Range Cancer Therapeutics ETF Expenses

TypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.79%0.56%0.54%0.48%0.51%
Other Expenses0.00%0.40%0.54%0.34%0.58%
Total Expense0.79%0.72%0.70%0.58%0.70%
Fee Waiver0.00%-0.53%-0.55%-0.22%-0.57%
Net Expense0.79%0.60%0.60%0.54%0.58%

Range Cancer Therapeutics ETF (CNCR) Holdings & Exposure

Top 10 CNCR Holdings

CNCR Sector Exposure

CNCR Industry Exposure

Full Holdings Details

CNCR ETF - Frequently Asked Questions

Are investors shorting Range Cancer Therapeutics ETF?

Range Cancer Therapeutics ETF saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 27,900 shares, a decline of 59.2% from the March 15th total of 68,300 shares. Based on an average daily trading volume, of 33,000 shares, the short-interest ratio is presently 0.8 days.
View Range Cancer Therapeutics ETF's Short Interest.

What does CNCR invest in?

Range Cancer Therapeutics ETF is a equity fund issued by Exchange Traded Concepts. CNCR focuses on health care investments and follows the Range Cancer Therapeutics Index. The fund's investments total to approximately $17.74 million assets under management.

What stocks does Range Cancer Therapeutics ETF hold?

CNCR invests in 79 holdings. Some of the stocks in their portfolio include Caribou Biosciences (CRBU), HUTCHMED (HCM), Recursion Pharmaceuticals (RXRX), Revolution Medicines (RVMD), EQRx (EQRX), Apollomics (APLM), VectivBio (VECT), Exscientia (EXAI), Immunocore (IMCR) and Exelixis (EXEL).

What is the management fee for Range Cancer Therapeutics ETF?

Range Cancer Therapeutics ETF's management fee is 0.79% and has no other recorded expenses or fee waivers. The net expense ratio for CNCR is 0.79%.

What other stocks do shareholders of Range Cancer Therapeutics ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Range Cancer Therapeutics ETF investors own include Micron Technology (MU), Intel (INTC), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA), Abbott Laboratories (ABT), Alibaba Group (BABA) and Quest Diagnostics (DGX).

This page (NASDAQ:CNCR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The #1 Crypto for 2024
InvestorPlace
Your Money is Not Safe
American Alternative